Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1661-1671

  Pitisuttithum, Punnee ^a   Gilbert, Peter ^d   Gurwith, Marc ^e   Heyward, William ^e   Martin, Michael ^c   Van Griensven, Fritz ^c   Hu, Dale ^f   Tappero, Jordan W ^c   Choopanya, Kachit ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Bangkok Metropolitan Administration   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d Fred Hutchinson Cancer Research Center   (United States)

^e VaxGen Inc   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120;

ACCIDENTAL INJURY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG OVERDOSE; EPIDEMIC; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SUICIDE; THAILAND; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND; VACCINATION; VIRAL LOAD;

EID: 33845433434     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508748     Document Type: Article

References (49)

1. Kitayaporn D, Vanichseni S, Mastro TD, et al. Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:289-95.
2. Wright NH, Vanichseni S, Akarasewi P, Wasi C, Choopanya K. Was the 1988 HIV epidemic among Bangkok's injecting drug users a common source outbreak? AIDS 1994; 8:529-32.
3. The Thai Working Group on HIV/AIDS Projection, March 2001. Projections for HIV/AIDS in Thailand: 2000-2020. Nonthaburi, Thailand: Division of AIDS, Department of Communicable Disease Control, Ministry of Public Health, 2001.
4. Phoolcharoen W, Ungchusak K, Sittitrai W, Brown T. Thailand: lessons from a strong national response to HIV/AIDS. AIDS 1998; 12 (Suppl B):S123-35.
5. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp 120 from the MN strain of HIV-1. JAMA 1994; 272:488-9.
6. Gorse GJ, Patel GB, Newman FK, et al. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induces by IIIB and MN recombinant gp120 vaccines. Clin Diagn Lab Immunol 1996;3:378-86.
7. Fultz PN, Nara P, Barre-Sinoussi F, et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992; 256:1687-90.
8. Migasena S, Suntharasamai P, Pitisuttithum P, et al. AIDSVAX® (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses 2000; 16:655-63.
9. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003; 188:219-27.
10. Vanichseni S, Kitayaporn D, Mastro TD, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001; 15:397-405.
11. MacQueen KM, Vanichseni S, Kitayaporn D, et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr 1999; 21:243-51.
12. Mastro TD, Kitayaporn D, Weninger BG, et al. Estimating the number of HIV-infected injection drug users in Bangkok: a capture-recapture method. Am J Public Health 1994; 84:1094-9.
13. Pitisuttithum P, Choopanya K, Vanichseni S, et al. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in a non-Western country. J Acquir Immune Defic Syndr (in press).
14. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S277-89.
15. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX™ to phase 3: safety, immunogenicity and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S325-31.
16. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 8:1887-95.
17. Herman PW, Huang W, Riddle L, et al. Development of bivalent (B/ E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999; 265:1-9.
18. Subbarao S, Vanichseni S, Hu DJ, et al. Genetic characterization of HIV-1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000; 16:699-707.
19. Phan K-O, Callahan ME, Vanichseni S, et al. A comparison of full-length gp120 from incident HIV-1 subtype E and B infections in Bangkok injecting drug users to prototype E and B strains that are components of a candidate vaccine. AIDS Res Hum Retroviruses 2000;16: 1445-50.
20. Centers for Disease Control and Prevention. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR Recomm Rep 1997; 46(RR-2):1-29.
21. Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004; 37:1160-5.
22. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
23. Ministry of Public Health. National guidelines for the clinical management of HIV infection in children and adults. 6th ed. Nonthaburi, Thailand: Division of AIDS, Department of Communicable Disease Control, Ministry of Public Health, 2000.
24. Ministry of Public Health. Guidelines for the care and treatment of HIV/AIDS in children and adults in Thailand. 7th ed. Nonthaburi, Thailand: Division of AIDS, Department of Communicable Disease Control, Ministry of Public Health, 2002.
25. Gilbert PB, Wei LJ, Kosorok MR, Clemens JD. Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics 2002; 58:773-80.
26. Borgan O, Langholz B, Samuelsen SO, Goldstein L, Pogoda J. Exposure stratified case-cohort designs. Lifetime Data Anal 2000; 6:39-58.
27. van Griensven F, Keawkungwal J, Vanichseni S, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX® B/E HIV vaccine efficacy trial in Bangkok, Thailand. AIDS 2004; 18:295-301.
28. Vanichseni S, Tappero JW, Pitisuttithum P, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX® B/E HIV vaccine trial, Bangkok, Thailand. AIDS 2004; 18:311-6.
29. Martin M, Mansakul W, Tappero JW, et al. Care and treatment of HIV-infected injecting drug users during an HIV vaccine efficacy trial, Bangkok, Thailand [abstract MoPe3350]. The XV International AIDS Conference (Bangkok) 2004. Available at: http://www.iasociety.org/ejias -search/search.asp. Accessed 11 July 2006.
30. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192:974-83.
31. Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type I infection. Lancet 1988; 1:790-4.
32. Mascola JR, Mathison BJ, Zack PM, Walker MC, Halstead SB, Burke DS. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 1993; 9:1175-84.
33. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-12.
34. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77.
35. Cohen J. Public health. AIDS vaccine still alive as booster after second failure in Thailand. Science 2003; 302:1309-10.
36. Hu DJ, Subbarao S, Vanichseni S, et al. Higher viral loads and other risk factors associated with HIV-1 seroconversion during a period of high HIV-1 incidence among injection drug users in Bangkok. J Acquir Immune Defic Syndr 2002; 30:240-7.
37. Nguyen L, Hu DJ, Choopanya K, at al. Genetic analysis of incident HIV-1 strains among injection drug users in Bangkok: evidence for multiple transmission clusters during a period of high incidence. J Acquir Immune Defic Syndr 2002; 30:248-56.
38. Hu DJ, Vanichseni S, Mock PA, et al. HIV-1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of an IgG capture BED enzyme immunoassay. AIDS Res Hum Retroviruses 2003; 19:727-30.
39. Hu DJ, Subbarao S, Vanichseni S, Mock PA, et al. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005; 19:303-8.
40. Wasi C, Herring B, Raktham S, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide binding enzyme immunoassay and heteroduplex mobility assay: evidence on increasing infection with HIV-1 subtype E. AIDS 1995; 9:843-9.
41. Kalish ML, Baldwin A, Raktham S, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 1995; 9:851-7.
42. Hu DJ, Vanichseni S, Mastro TD, et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001; 15:683-91.
43. Buchacz K, Hu DJ, Vanichseni S, Mock H, et al. Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials. J Acquir Immune Defic Syndr 2004; 36:853-60.
44. Nguyen L, Li M, Chaowanachan T, Vanichseni S, et al. CCR5 promoter human haplogroups associated with HIV-1 disease progression in Thai injection drug users. AIDS 2004; 18:1327-33.
45. van Griensven F, Pitisuttithum P, Vanichseni S, et al. Trends in the injection of midazolam and other drugs and needle sharing among injection drug users enrolled in the AIDSVAX B/E HIV-1 vaccine trial in Bangkok, Thailand. Int J Drug Policy 2005; 16:171-5.
46. Vongchak T, Kawichai S, Sherman S, et al. The influence of Thailand's 2003 'war on drugs' policy on self-reported drug use among injection drug users in Chiang Mai, Thailand. Int J Drug Policy 2005; 16:115-21.
47. Bureau of Health Service System Development. Number of IDU in treatment in Bangkok, 1991-2004. Nonthaburi, Thailand: Department of Health Services, Ministry of Public Health, 2005.
48. Thailand's "war on drugs." The Wire: Amnesty International's monthly magazine, 2003. Available at: http://web.amnesty.org/web/wire.nsf/ May2003/Thailand. Accessed 15 May 2006.
49. Centers for Disease Control and Prevention (CDC). CDC trials of daily oral tenofovir for preventing HIV infection: phase II and III clinical trails in Botswana, Thailand, and the United States. CDC, 2004. Available at: http://www.cdc.gov/hiv/pubs/TenofovirFactSheet.pdf. Accessed 13 December 2005.